Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group has enrolled the first subject in a Phase II clinical trial in China for its in-house developed drug LY03020, a first-in-class agonist targeting both TAAR1 and 5-HT2C receptors. The candidate is being developed to treat acute schizophrenia and is also intended for Alzheimer’s disease psychosis and bipolar disorder, addressing a large unmet need where many patients do not respond adequately to current antipsychotics.
The multicenter, randomized, double-blind, placebo-controlled study in China will evaluate LY03020’s efficacy, safety, pharmacokinetics, and effective dosing in acute schizophrenia, complementing cleared clinical development in the U.S. Early data suggest the drug may improve positive, negative, and cognitive symptoms with fewer side effects such as extrapyramidal symptoms and metabolic issues, potentially strengthening Luye Pharma’s competitive positioning in the CNS segment if later-stage results confirm these benefits.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group is a Bermuda-incorporated biopharmaceutical company focused on developing innovative central nervous system therapies. The group leverages its New Chemical Entity and New Therapeutic Entity platforms to create next-generation drugs for neurological and psychiatric disorders, with parallel development strategies in China and overseas markets.
Average Trading Volume: 20,115,474
Technical Sentiment Signal: Hold
Current Market Cap: HK$11.47B
Learn more about 2186 stock on TipRanks’ Stock Analysis page.